Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia

Fundamental and Clinical Pharmacology

Volumn 24, Issue 4, 2010, Pages 457-462

  Konishi, Hiroki ^a,b   Fukushima, Keizo ^b,c   Sudo, Masatomo ^b   Sumi, Masaki ^b   Minouchi, Tokuzo ^b   Iga, Ikumi ^a   Shibata, Nobuhito ^d   Takada, Kanji ^c   Yamaji, Akira ^b  

^a OSAKA OHTANI UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^d DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

cholestasis; hyperbilirubinemia; micafungin; pharmacokinetics; rats

Indexed keywords

BILIRUBIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HYPERBILIRUBINEMIA; LABORATORY TEST; LIVER FUNCTION; MALE; METABOLIC CAPACITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFUNGAL AGENTS; BILE; BILIRUBIN; CHOLESTASIS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; HYPERBILIRUBINEMIA; INJECTIONS, INTRAVENOUS; LIPOPEPTIDES; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77954400451     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00785.x     Document Type: Article

References (27)

1. ®). Jpn. J. Med. Mycol. (2005) 46 217 222. (Pubitemid 41598005)
2. Joseph J.M., Jain R., Danziger L.H. Micafungin: a new echinocandin antifungal. Pharmacotherapy (2007) 27 53 67. (Pubitemid 46067963)
3. Kurtz M.B., Heath I.B., Marrinan J., Dreikorn S., Onishi J., Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 79 1480 1489. (Pubitemid 24203556)
4. Tomishima M., Ohki H., Yamada A. et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J. Antibiot. (Tokyo) (1999) 52 674 676. (Pubitemid 29378227)
5. Hatano K., Morishita Y., Nakai T., Ikeda F. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. (Tokyo) (2002) 79 219 222. (Pubitemid 34285463)
6. Azuma J., Nakahara K., Kagayama A. et al. Phase study of micafungin. Jpn. J. Chemother. (2002) 50 (suppl 1) 104 147.
7. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr. Clin. Pharmacol. (2007) 2 37 58. (Pubitemid 46723129)
8. Tabata K., Katashima M., Kawamura A., Kaibara A., Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab. Pharmacokinet. (2006) 21 324 331.
9. Nakagawa Y., Ichii Y., Saeki Y., Kodaka M., Suzuki K., Kishino S. Plasma concentration of micafungin in patients with hematologic malignancies. J. Infect. Chemother. (2007) 13 39 45. (Pubitemid 46356242)
10. Nakagawa Y., Ichii Y, Saeki Y., Kodama M., Kishino S., Suzuki K. Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies. Eur. J. Drug Metab. Pharmacokinet. (2008) 33 191 198.
11. Shimoeda S., Ohta S., Kobayashi H. et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol. Pharm. Bull. (2005) 28 477 480. (Pubitemid 40879971)
12. Yamato Y., Kaneko H., Tanimoto K. et al. Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn. J. Chemother. (2002) 50 (suppl 1) 68 73. (Pubitemid 36033011)
13. ®, Xenobio. Metabol. Dispos. (1999) 21 286 293.
14. Hebert M.F., Smith H.E., Marbury T.C. et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. (2005) 45 1145 1152.
15. Pereira R.M., dos Santos R.A., Oliveira E.A. et al. Development of hepatorenal syndrome in bile duct ligated rats. World J. Gastroenterol. (2008) 14 4505 4511.
16. 14C] micafungin to rats. Jpn. J. Chemother. (2002) 50 (suppl 1) 80 87. (Pubitemid 36033013)
17. Kaneko H., Yamato Y., Teramura Y. et al. Metabolites of micafungin in rats and dogs. Jpn. J. Chemother. (2002) 50 (suppl1) 88 93. (Pubitemid 36033014)
18. Chen J., Farrell G.C. Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J. Gastroenterol. Hepatol. (1996) 11 870 877. (Pubitemid 26297943)
19. Tateishi T., Watanabe M., Nakura H., Tanaka M., Kumai T., Kobayashi S. Liver damage induced by bile duct ligation affects CYP isoenzymes differently in rats. Pharmacol. Toxicol. (1998) 82 89 92. (Pubitemid 28064624)
20. Konishi H., Sudo M., Sumi M. et al. Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure. Biol. Pharm. Bull. (2005) 28 556 559. (Pubitemid 40879990)
21. Tuchweber B., Desmoulière A., Bochaton-Piallat M.L., Rubbia-Brandt L., Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab. Invest. (1996) 74 265 278. (Pubitemid 26041028)
22. Saito J.M., Maher J.J. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant. Gastroenterology (2000) 118 1157 1168.
23. Bomzon A., Weinbroum A., Kamenetz L. Systemic hypotension and pressor responsiveness in cholestasis. A study in conscious 3-day bile duct ligated rats. J. Hepatol. (1990) 11 70 76. (Pubitemid 20250830)
24. Kaneko H., Yamato Y., Hashimoto T. et al. Drug interactions of micafungin in vitro. Jpn. J. Chemother. (2002) 50 (suppl 1) 94 103. (Pubitemid 36033015)
25. Abe F., Ueyama J., Kawasumi N. et al. Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats. Antimicrob. Agents Chemother. (2008) 52 3454 3456.
26. Kishino S., Ohno K., Shimamura T., Furukawa H., Todo S. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin. Transplant. (2004) 18 676 680. (Pubitemid 39496980)
27. Hirata K., Aoyama T., Matsumoto Y. et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi (2007) 127 897 901. (Pubitemid 46684737)